ClinicalTrials.gg
RecruitingNCT06974617Updated May 16, 2025

Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine

An interventional study of Sphenopalatine block and Botulinum Toxin Type A in Sphenopalatine Block, BOTOX and Chronic Migraine, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing lidocaine in Migraine Disorders — 5 open to participants now, 5 under way, none of them phase 3. Lidocaine · Migraine Disorders.

Planned enrollment
5th of 13
64 · median 50
Started
2025
with 2 others
No phase
4 of 13
2 open now
Registered
10th of 13
by date
Lead sponsor
1 of 13
Cairo University

Among the 13 studies testing lidocaine in Migraine Disorders, this one is the 5th largest by planned enrollment, is one of 3 that started in 2025, is one of 4 with no phase, and was the 10th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

5 of the 13 studies testing lidocaine in Migraine Disorders are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About lidocaine

Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing lidocaine in Migraine Disorders, or all of them as a file.
02

Study summary

This trial compares the efficacy and safety of sphenopalatine ganglion block (SPGB) and intramuscular BOTOX injection in chronic migraine.

Read the detailed description

The International Headache Society's Headache Classification Committee recognizes three broad categories of headaches: primary headaches, secondary headaches, and a third catchall category called "painful cranial neuropathies, other facial pain, and other headaches." Migraines fall into the primary headache category.

Sphenopalatine ganglion (SPG), or the pterygopalatine ganglion (PPG), is a large extracranial parasympathetic ganglion with multiple neural connections, including autonomic and motor.

The botulinum toxin (BOTOX®), which can exert a paralytic effect by binding to presynaptic cholinergic nerve terminals at the neuromuscular junction, is produced by the Gram-positive, rod-shaped, spore-forming, anaerobic bacterium Clostridium botulinum. It internalizes and inhibits the exocytosis of the neurotransmitter acetylcholine by decreasing the frequency of acetylcholine release

03

Conditions studied

  • Sphenopalatine Block
  • BOTOX
  • Chronic Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 and 65 years.
  • Both sexes.
  • Chronic migraine. Chronic migraine, defined as headaches on ≥15 days per month for ≥3 months, of which ≥8 days meet criteria for migraine without aura or respond to migraine-specific treatment according to International Classification of Headache Disorders-3 Beta.

Exclusion criteria

Exclusion Criteria:

  • Patients with medication over use headache.
  • Bleeding disorders.
  • Abnormal neurological examination.
  • History of allergy to local anesthetics or BOTOX.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Sphenopalatine block group

    Patients will receive 2 ml of 2% lidocaine using a nasal applicator in each nostril.

    Drug: Sphenopalatine block

  • Experimental
    BOTOX group

    Patients will receive Botulinum Toxin Type A 100 units administered in a fixed dose and site paradigm.

    Drug: Botulinum Toxin Type A

Interventions

  • DrugLidocaineStudies of LidocaineLidocaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive 2 ml of 2% lidocaine using a nasal applicator in each nostril.

    Also known as: Lidocaine

  • Patients will receive Botulinum Toxin Type A 100 units administered in a fixed dose and site paradigm.

06

What researchers measure

Primary outcomes

  1. Degree of pain

    The patients will be shown how to use the Visual Analogue Scale (VAS); 0-10 point where 0 = no pain and 10 = worst imaginable pain. VAS will be noted as well as after procedure, four-week, and 12-weeks period.

    Time frame: 12 weeks post-procedure

Secondary outcomes

  1. Percentage of patients free of headache

    The percentage of patients free of headache at baseline (just before the procedure), after procedure, four-week, and 12-weeks period.

    Time frame: 12 weeks post-procedure

  2. Headache relief rate

    Headache relief rate (percentage of patients with 50% or more reduction in headache intensity at four-week and 12-weeks period).

    Time frame: 12 weeks post-procedure

07

Study locations

1 of 1 sites recruiting
  • Cairo University
    Cairo, 12613, Egypt
    Recruiting
    • Mohamed E Abdel Fattah, MD · Contactmohamed-elsaid@cu.edu.eg · 00201284475792
    • Samuel F Samy, MD · Principal investigator
    • Amany M Abo Taleb, MD · Principal investigator
    • Mohammed S ElSharkawy, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

Time frame: After the end of study for one year.

Access criteria: The data will be available upon a reasonable request from the corresponding author.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Oct 2025, 4 months after the start.

Of 310 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 4 months is below that.

Counting every sponsor, half of 360 studies reached it within 15 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
May 16, 2025
StartActual
May 15, 2025
Primary completionEst.
Oct 1, 2025
CompletionEst.
Oct 1, 2025
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06974617
Lead sponsor
Cairo University
Responsible party
Mohamed Elsaid Abdel Fattah (Lecturer of Anesthesia, Surgical ICU and Pain Management, Faculty of Medicine, National Cancer Institute, Cairo University, Egypt., Cairo University) — Principal investigator
First posted
May 16, 2025
Start date
May 15, 2025
Primary completion
Oct 1, 2025 (estimated)
Completion
Oct 1, 2025 (estimated)
Last update
May 16, 2025

Study contacts

Mohamed E Abdel Fattah, MD
Contact
mohamed-elsaid@cu.edu.eg
00201284475792

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lidocaine · Botulinum toxin type A

Start the discussion